1 Poxviridae Infections Drug Market Overview
1.1 Poxviridae Infections Drug Product Scope
1.2 Poxviridae Infections Drug Segment by Type
1.2.1 Global Poxviridae Infections Drug Sales by Type (2020-2026)
1.2.2 CJ-40011
1.2.3 24a
1.2.4 BA-368
1.2.5 Others
1.3 Poxviridae Infections Drug Segment by Application
1.3.1 Global Poxviridae Infections Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Poxviridae Infections Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Poxviridae Infections Drug Sales Growth Rate (2015-2026)
1.4.2 Global Poxviridae Infections Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Poxviridae Infections Drug Price Trends (2015-2026)
2 Poxviridae Infections Drug Estimate and Forecast by Region
2.1 Global Poxviridae Infections Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Poxviridae Infections Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Poxviridae Infections Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Poxviridae Infections Drug Revenue Market Share by Region (2015-2020)
2.3 Global Poxviridae Infections Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Poxviridae Infections Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Poxviridae Infections Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.2 Europe Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.3 China Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.4 Japan Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.6 India Poxviridae Infections Drug Estimates and Projections (2015-2026)
3 Global Poxviridae Infections Drug Competition Landscape by Players
3.1 Global Top Poxviridae Infections Drug Players by Sales (2015-2020)
3.2 Global Top Poxviridae Infections Drug Players by Revenue (2015-2020)
3.3 Global Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Poxviridae Infections Drug as of 2019)
3.4 Global Poxviridae Infections Drug Average Price by Company (2015-2020)
3.5 Manufacturers Poxviridae Infections Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Poxviridae Infections Drug Players (Opinion Leaders)
4 Global Poxviridae Infections Drug Market Size by Type
4.1 Global Poxviridae Infections Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Poxviridae Infections Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Poxviridae Infections Drug Price by Type (2015-2020)
4.2 Global Poxviridae Infections Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Poxviridae Infections Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Poxviridae Infections Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Poxviridae Infections Drug Price Forecast by Type (2021-2026)
5 Global Poxviridae Infections Drug Market Size by Application
5.1 Global Poxviridae Infections Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Poxviridae Infections Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Poxviridae Infections Drug Price by Application (2015-2020)
5.2 Global Poxviridae Infections Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Poxviridae Infections Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Poxviridae Infections Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Poxviridae Infections Drug Price Forecast by Application (2021-2026)
6 United States Poxviridae Infections Drug Market Facts & Figures
6.1 United States Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
6.2 United States Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
6.3 United States Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
7 Europe Poxviridae Infections Drug Market Facts & Figures
7.1 Europe Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
7.2 Europe Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
7.3 Europe Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
8 China Poxviridae Infections Drug Market Facts & Figures
8.1 China Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
8.2 China Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
8.3 China Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
9 Japan Poxviridae Infections Drug Market Facts & Figures
9.1 Japan Poxviridae Infections Drug Sales Market Share by Company (3015-3030)
9.2 Japan Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
9.3 Japan Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
10 Southeast Asia Poxviridae Infections Drug Market Facts & Figures
10.1 Southeast Asia Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
11 India Poxviridae Infections Drug Market Facts & Figures
11.1 India Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
11.2 India Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
11.3 India Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Poxviridae Infections Drug Business
12.1 Bavarian Nordic A/S
12.1.1 Bavarian Nordic A/S Corporation Information
12.1.2 Bavarian Nordic A/S Business Overview
12.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Products Offered
12.1.5 Bavarian Nordic A/S Recent Development
12.2 BioFactura, Inc.
12.2.1 BioFactura, Inc. Corporation Information
12.2.2 BioFactura, Inc. Business Overview
12.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 BioFactura, Inc. Poxviridae Infections Drug Products Offered
12.2.5 BioFactura, Inc. Recent Development
12.3 CEL-SCI Corporation
12.3.1 CEL-SCI Corporation Corporation Information
12.3.2 CEL-SCI Corporation Business Overview
12.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 CEL-SCI Corporation Poxviridae Infections Drug Products Offered
12.3.5 CEL-SCI Corporation Recent Development
12.4 Chimerix, Inc.
12.4.1 Chimerix, Inc. Corporation Information
12.4.2 Chimerix, Inc. Business Overview
12.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Chimerix, Inc. Poxviridae Infections Drug Products Offered
12.4.5 Chimerix, Inc. Recent Development
12.5 China Biologic Products, Inc.
12.5.1 China Biologic Products, Inc. Corporation Information
12.5.2 China Biologic Products, Inc. Business Overview
12.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Products Offered
12.5.5 China Biologic Products, Inc. Recent Development
12.6 CJ HealthCare Corp.
12.6.1 CJ HealthCare Corp. Corporation Information
12.6.2 CJ HealthCare Corp. Business Overview
12.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Products Offered
12.6.5 CJ HealthCare Corp. Recent Development
12.7 EpiVax, Inc.
12.7.1 EpiVax, Inc. Corporation Information
12.7.2 EpiVax, Inc. Business Overview
12.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 EpiVax, Inc. Poxviridae Infections Drug Products Offered
12.7.5 EpiVax, Inc. Recent Development
12.8 N & N Pharmaceuticals Inc.
12.8.1 N & N Pharmaceuticals Inc. Corporation Information
12.8.2 N & N Pharmaceuticals Inc. Business Overview
12.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
12.8.5 N & N Pharmaceuticals Inc. Recent Development
12.9 SIGA Technologies, Inc.
12.9.1 SIGA Technologies, Inc. Corporation Information
12.9.2 SIGA Technologies, Inc. Business Overview
12.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Products Offered
12.9.5 SIGA Technologies, Inc. Recent Development
12.10 Takeda Pharmaceutical Company Limited
12.10.1 Takeda Pharmaceutical Company Limited Corporation Information
12.10.2 Takeda Pharmaceutical Company Limited Business Overview
12.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Products Offered
12.10.5 Takeda Pharmaceutical Company Limited Recent Development
12.11 Tonix Pharmaceuticals Holding Corp.
12.11.1 Tonix Pharmaceuticals Holding Corp. Corporation Information
12.11.2 Tonix Pharmaceuticals Holding Corp. Business Overview
12.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Products Offered
12.11.5 Tonix Pharmaceuticals Holding Corp. Recent Development
12.12 Verrica Pharmaceuticals Inc.
12.12.1 Verrica Pharmaceuticals Inc. Corporation Information
12.12.2 Verrica Pharmaceuticals Inc. Business Overview
12.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
12.12.5 Verrica Pharmaceuticals Inc. Recent Development
13 Poxviridae Infections Drug Manufacturing Cost Analysis
13.1 Poxviridae Infections Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Poxviridae Infections Drug
13.4 Poxviridae Infections Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Poxviridae Infections Drug Distributors List
14.3 Poxviridae Infections Drug Customers
15 Market Dynamics
15.1 Poxviridae Infections Drug Market Trends
15.2 Poxviridae Infections Drug Opportunities and Drivers
15.3 Poxviridae Infections Drug Market Challenges
15.4 Poxviridae Infections Drug Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
【掲載企業】
Bavarian Nordic A/S、BioFactura, Inc.、CEL-SCI Corporation、Chimerix, Inc.、China Biologic Products, Inc.、CJ HealthCare Corp.、EpiVax, Inc.、N & N Pharmaceuticals Inc.、SIGA Technologies, Inc.、Takeda Pharmaceutical Company Limited、Tonix Pharmaceuticals Holding Corp.、Verrica Pharmaceuticals Inc.
【免責事項】
https://www.globalresearch.jp/disclaimer